Printer Friendly

Articles from M2 Pharma (December 5, 2018)

1-11 out of 11 article(s)
Title Author Type Words
Blaze Bioscience Initiates Pivotal Clinical Trial for Tumor Paint: BLZ-100 and the Canvas Imaging System. 455
Bruin Biometrics wins USD1.4m NIH grant to support early detection of knee implant failures. 202
Changzhou Qianhong Bio-pharma starts phase two construction of pharmaceuticals production facility. 156
European Commission Approves Merck's Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and Pifeltro (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate ... 428
IDEAYA Biosciences names Bao Truong as VP of Regulatory Affairs. 177
Innovent to launch clinical trials of Anti-OX40 Monoclonal Antibody IBI101 upon US FDA approval. 254
Momenta Pharmaceuticals revises US M923 regulatory strategy. 137
Novartis receives US FDA priority review for Zolgensma. 170
Peak Health launches Phyto Farmacy. 187
PhyNexus Inc to be merged with Biotage AB. 281
TRIGR Therapeutics expands bispecific immuno-oncology range. 167

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters